Trevi Therapeutics to Participate in Upcoming March Conferences

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in two March 2026 industry events: the Leerink Partners 2026 Global Healthcare Conference in Miami and the Access USA Rare Disease Summit in Philadelphia.

Presentations include a March 11 fireside chat with Jennifer Good and James Cassella and a March 18 panel session featuring Farrell Simon. A live webcast link is provided for the Leerink fireside chat.

News Market Reaction – TRVI

+5.45%

20 alerts

+5.45% News Effect

-9.0% Trough in 5 hr 2 min

+$85M Valuation Impact

$1.64B Market Cap

0.5x Rel. Volume

On the day this news was published, TRVI gained 5.45%, reflecting a notable positive market reaction. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $85M to the company's valuation, bringing the market cap to $1.64B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Leerink conference dates: March 8–11, 2026 Leerink fireside chat: March 11, 8:40 a.m. ET Rare Disease Summit dates: March 17–19, 2026 +1 more

4 metrics

Leerink conference dates March 8–11, 2026 Leerink Partners 2026 Global Healthcare Conference

Leerink fireside chat March 11, 8:40 a.m. ET Trevi fireside chat timing

Rare Disease Summit dates March 17–19, 2026 Access USA, Rare Disease Summit 2026

Rare Disease panel time March 18, 9:00–9:45 a.m. ET Panel on rare disease launch excellence

Market Reality Check

Price: $12.57 Vol: Volume 1,305,049 is in li...

normal vol

$12.57 Last Close

Volume Volume 1,305,049 is in line with 20-day average 1,283,167 (relative 1.02x). normal

Technical Price 11.92 is trading above 200-day MA at 9.26 and 17.16% below the 52-week high 14.39.

Peers on Argus

TRVI gained 3.47% while close peers were mixed: DNTH +3.84%, ELVN +1.82%, GPCR -...

1 Up 1 Down

TRVI gained 3.47% while close peers were mixed: DNTH +3.84%, ELVN +1.82%, GPCR -1.84%, LENZ -0.07%, TRML 0%. Momentum scanner also showed XERS up 10.78% and NTLA down 5.73%, indicating stock-specific rather than broad sector-driven action.

Historical Context

5 past events · Latest: Feb 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Conference participation	Neutral	-2.4%	Management fireside chat at Oppenheimer healthcare conference.
Jan 22	Clinical data publication	Positive	+6.2%	Phase 2b CORAL IPF chronic cough results published in JAMA.
Jan 15	Dividend tax disclosure	Neutral	-2.6%	Getty Realty detailed 2025 dividend tax allocation per share.
Jan 8	Strategic pipeline update	Positive	-4.3%	Plans for FDA End-of-Phase 2 meeting and Phase 3, RCC trials.
Dec 4	CFO appointment	Positive	-1.7%	Appointment of David Hastings as CFO to support Phase 3 progress.

Pattern Detected

Positive clinical and strategic updates have shown mixed follow-through, with some selloffs after seemingly favorable news, while strong clinical data publication drew a positive reaction.

Recent Company History

Over the past few months, Trevi has highlighted multiple milestones: a JAMA publication of Phase 2b CORAL IPF chronic cough data on Jan 22, 2026 with a 6.21% next-day rise, and strategic plans on Jan 8, 2026 to hold an FDA End-of-Phase 2 meeting and start Phase 3 and RCC trials, which saw a -4.27% move. Conference-participation news on Feb 17, 2026 corresponded to a modest -2.4% reaction. Today’s March conference participation continues this pattern of visibility-focused, non-data announcements between key clinical steps.

Market Pulse Summary

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with Tre...

Analysis

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with Trevi’s established clinical story rather than new data, as this news centers on March conference participation and visibility events. Earlier conference news on Feb 17, 2026 was followed by a -2.4% move, while the JAMA Phase 2b publication on Jan 22, 2026 saw a 6.21% gain. Any outsized rally on this non-fundamental update would therefore represent a deviation from the more muted responses to similar participation announcements.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough, oral nalbuphine er

4 terms

idiopathic pulmonary fibrosis medical

"therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF),"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

oral nalbuphine er medical

"developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough"

An oral nalbuphine ER is a slow‑release pill form of nalbuphine, an opioid pain medicine that activates some pain‑blocking pathways while dampening others, which can lower certain side effects and abuse risk compared with traditional opioids. For investors, it signals a product with potential market demand for longer‑lasting, outpatient pain control, but its commercial value depends on clinical benefits, regulatory approval, patent protection and how payers and prescribers view its safety and cost — like a timed-release version of a familiar pain drug.

AI-generated analysis. Not financial advice.

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March.

Leerink Partners 2026 Global Healthcare Conference
March 8 – 11, 2026, Miami, Florida
Fireside Chat: March 11, 8:40 a.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO
Register here to watch the live webcast.

Access USA, Rare Disease Summit 2026
March 17 – 19, 2026, Philadelphia, Pennsylvania
Panel: Architecting Success – Building a Foundation for Rare Disease Launch Excellence
Session: March 18, 9:00 – 9:45 a.m. ET
Trevi Representative: Farrell Simon, Pharm.D., CCO

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact 
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

FAQ

When will Trevi Therapeutics (TRVI) present at the Leerink Partners 2026 Global Healthcare Conference?

Trevi will appear at Leerink on March 11, 2026, for a fireside chat at 8:40 a.m. ET. According to the company, Jennifer Good and James Cassella will participate and a live webcast is available for investors to watch.

Who represents Trevi Therapeutics (TRVI) at the Access USA Rare Disease Summit in March 2026?

Trevi is represented by Farrell Simon, Pharm.D., at the Access USA Rare Disease Summit on March 18, 2026. According to the company, she will take part in the panel "Architecting Success – Building a Foundation for Rare Disease Launch Excellence."

How can investors watch Trevi Therapeutics (TRVI) management at the March 11, 2026 fireside chat?

Investors can watch the March 11 fireside chat via a live webcast provided by the company. According to the company, a registration link is available to access the live webcast of the Leerink conference session.

What topics will Trevi Therapeutics (TRVI) discuss at the March 2026 conferences?

Trevi's sessions focus on corporate and rare-disease commercial topics, including a fireside chat and a panel on launch excellence. According to the company, discussions will involve leadership perspectives and strategies relevant to investors and stakeholders.

Which Trevi Therapeutics (TRVI) executives will appear at the March 2026 Leerink and Access USA events?

Trevi will send Jennifer Good (President and CEO) and James Cassella (Ph.D., CDO) to Leerink, and Farrell Simon (Pharm.D., CCO) to Access USA. According to the company, these executives will present on March 11 and March 18, respectively.